Natco Pharma (India) Performance
| NATCOPHARM | 1,376 38.05 2.84% |
The company secures a Beta (Market Risk) of 0.39, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Natco Pharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding Natco Pharma is expected to be smaller as well. At this point, Natco Pharma Limited has a negative expected return of -0.16%. Please make sure to verify Natco Pharma's maximum drawdown, accumulation distribution, as well as the relationship between the Accumulation Distribution and market facilitation index , to decide if Natco Pharma Limited performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Natco Pharma Limited has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest weak performance, the Stock's basic indicators remain strong and the recent confusion on Wall Street may also be a sign of long-lasting gains for the firm traders. ...more
Forward Dividend Yield 0.0042 | Payout Ratio 0.053 | Last Split Factor 5:1 | Forward Dividend Rate 5.75 | Ex Dividend Date 2024-11-27 |
1 | Trade Spotlight How should you trade Bajaj Finance, Nestle, Indian Hotels, Natco Pharma, Havells and... - Moneycontrol | 09/18/2024 |
2 | Natco Pharma Ltd. Stock Sees Dip, But Long-Term Outlook Remains Positive - MarketsMojo | 10/25/2024 |
3 | Earnings Beat NATCO Pharma Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - Simply Wall St | 11/14/2024 |
4 | NATCO Pharma Limited Passed Our Checks, And Its About To Pay A 1.50 Dividend - Simply Wall St | 11/22/2024 |
| Begin Period Cash Flow | 1.4 B | |
| Free Cash Flow | 8.9 B |
Natco |
Natco Pharma Relative Risk vs. Return Landscape
If you would invest 153,585 in Natco Pharma Limited on September 2, 2024 and sell it today you would lose (16,035) from holding Natco Pharma Limited or give up 10.44% of portfolio value over 90 days. Natco Pharma Limited is generating negative expected returns and assumes 1.6666% volatility on return distribution over the 90 days horizon. Simply put, 14% of stocks are less volatile than Natco, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Natco Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Natco Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Natco Pharma Limited, and traders can use it to determine the average amount a Natco Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0951
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | NATCOPHARM |
Estimated Market Risk
| 1.67 actual daily | 14 86% of assets are more volatile |
Expected Return
| -0.16 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.1 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Natco Pharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Natco Pharma by adding Natco Pharma to a well-diversified portfolio.
Natco Pharma Fundamentals Growth
Natco Stock prices reflect investors' perceptions of the future prospects and financial health of Natco Pharma, and Natco Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Natco Stock performance.
| Return On Equity | 0.31 | ||||
| Return On Asset | 0.19 | ||||
| Profit Margin | 0.43 % | ||||
| Operating Margin | 0.55 % | ||||
| Current Valuation | 223.82 B | ||||
| Shares Outstanding | 179.11 M | ||||
| Price To Book | 3.45 X | ||||
| Price To Sales | 5.40 X | ||||
| Revenue | 40.02 B | ||||
| Gross Profit | 20.54 B | ||||
| EBITDA | 18.8 B | ||||
| Net Income | 13.88 B | ||||
| Cash And Equivalents | 4.14 B | ||||
| Total Debt | 3.86 B | ||||
| Book Value Per Share | 399.14 X | ||||
| Cash Flow From Operations | 12.52 B | ||||
| Earnings Per Share | 108.66 X | ||||
| Total Asset | 69.06 B | ||||
| Retained Earnings | 44.66 B | ||||
About Natco Pharma Performance
By evaluating Natco Pharma's fundamental ratios, stakeholders can gain valuable insights into Natco Pharma's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Natco Pharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Natco Pharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Natco Pharma is entity of India. It is traded as Stock on NSE exchange.Things to note about Natco Pharma Limited performance evaluation
Checking the ongoing alerts about Natco Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Natco Pharma Limited help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Natco Pharma Limited generated a negative expected return over the last 90 days | |
| Natco Pharma Limited is unlikely to experience financial distress in the next 2 years | |
| About 51.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: NATCO Pharma Limited Passed Our Checks, And Its About To Pay A 1.50 Dividend - Simply Wall St |
- Analyzing Natco Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Natco Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Natco Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Natco Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Natco Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Natco Pharma's stock. These opinions can provide insight into Natco Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Natco Stock analysis
When running Natco Pharma's price analysis, check to measure Natco Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Natco Pharma is operating at the current time. Most of Natco Pharma's value examination focuses on studying past and present price action to predict the probability of Natco Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Natco Pharma's price. Additionally, you may evaluate how the addition of Natco Pharma to your portfolios can decrease your overall portfolio volatility.
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |